このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Inter- and Intra-Rater Reliability of a Wearable Inertial Sensor for Spatiotemporal Gait Assessment in Stroke Survivors

2026年6月10日 更新者:Alejandro Herrera Rojas、Neuron, Spain

Background and Objective:

Stroke frequently impairs gait functionality, leading to significant limitations in functional independence and quality of life. Objective gait analysis is essential for evaluating clinical status and rehabilitation progress. While laboratory-bound, non-wearable systems are considered the gold standard, their high cost, complex infrastructure, and requirement for specialized personnel limit their routine implementation in daily clinical practice. Portable inertial measurement units have emerged as a practical, low-cost alternative for motion analysis outside traditional laboratory settings. However, evidence regarding specific commercial devices in pathological populations remains limited. This study aims to evaluate the inter-rater and intra-rater reliability of the commercially available Baiobit® lumbar-mounted inertial sensor for measuring spatiotemporal gait parameters in stroke survivors.

Methodology:

A prospective, single-group, repeated-measures design was conducted at a specialized neurorehabilitation clinic (Neuron Clinic, Madrid). A convenience sample of 22 adults diagnosed with subacute or chronic stroke who were able to ambulate independently was included. Gait assessments were performed by two trained evaluators across two separate sessions spaced 24 to 48 hours apart. During each session, the Baiobit® sensor was secured to the participants' sacral region (S1-S2) using an adjustable belt. Participants performed three 10-meter walking trials at their comfortable, self-selected pace for each evaluator. Reliability was quantified using Intraclass Correlation Coefficients (ICC), Standard Error of Measurement (SEM), and Minimal Detectable Change (MDC).

Expected Outcomes:

It is hypothesized that the Baiobit® inertial sensor will demonstrate adequate relative and absolute inter- and intra-rater reliability across spatiotemporal gait parameters, supporting its viability as an objective monitoring tool in routine stroke rehabilitation clinical settings.

調査の概要

状態

完了

条件

詳細な説明

Introduction and Rationale Stroke survivors commonly experience sensorimotor sequelae that heavily compromise walking patterns, typically presenting reduced speed, lower cadence, shortened step length, and prolonged double-support time. Objective quantification of these spatiotemporal parameters is critical to direct therapeutic goals and evaluate rehabilitation outcomes. To overcome the financial and logistical barriers of traditional motion laboratories, wearable inertial measurement units (IMUs) are increasingly proposed due to their portability and ease of use. However, substantial heterogeneity in sensor configurations and algorithms necessitates population-specific metric validation. The Baiobit® system is an emerging commercial IMU that integrates a triaxial accelerometer, gyroscope, and magnetometer operating at 200 Hz to estimate gait metrics via internal event-detection algorithms. To date, no study has established its measurement consistency and repeatability specifically for stroke survivors.

Study Population and Eligibility Participants were recruited via convenience sampling from the outpatient database at Neuron Clinics in Madrid, Spain. To ensure safety and protocol compliance, strict eligibility criteria were applied: Inclusion Criteria: (1) Adults aged 18 to 85 years; (2) a confirmed diagnosis of ischemic or hemorrhagic stroke with a time since onset $> 1$ month; (3) ability to ambulate independently (Functional Ambulation Categories FAC > 4) regardless of foot-up orthosis use; (4) capacity to walk 10 meters without stopping and repeat the trial six times across the protocol; and (5) cognitive ability to understand instructions and provide written informed consent. Exclusion Criteria: (1) Medical instability or acute conditions comprising gait safety; (2) concomitant neurological conditions other than stroke; (3) severe musculoskeletal disorders interfering with locomotion; (4) visual or auditory deficits severely impairing balance; (5) recent use of medications affecting gait or postural control (e.g., benzodiazepines, antipsychotics, or opioids); and (6) pregnancy. Randomization and Blinding Protocols To control for sequence and order biases, a 1:1 block randomization scheme was generated using a digital tool (randomizer.org) to determine the evaluation sequence between the two raters. Blinding was coordinated by a third independent researcher who managed the logistical workflows, handled independent password-protected software accounts for each rater, and exported raw data to a masked master database. This design strictly prevented the two evaluators from assessing participants simultaneously or accessing each other's data records.

Experimental Procedures The data collection protocol spanned two distinct evaluation sessions scheduled 24 to 48 hours apart to minimize clinical fluctuations while preventing recall bias. Familiarization: In the first session, after formal enrollment and collection of sociodemographic data, participants were familiarized with the environment, and the 10-meter walkway was demonstrated. Sensor Placement: The Baiobit® sensor was securely mounted on the sacral region corresponding to the S1-S2 vertebrae using the manufacturer's adjustable elastic belt. Data Acquisition: Participants performed three 10-meter walking trials at their comfortable, self-selected pace per evaluator. The first assigned evaluator positioned the sensor, acquired the recordings, and completely removed the device. Rest Period: A mandatory 10-minute seated rest period was enforced between evaluators to mitigate fatigue effects. Replication: The second evaluator repeated the exact preparation, placement, and trial recording steps. This identical sequence was replicated during the second session under unvaried environmental conditions.

Outcome Measures and Biomechanical Variables Spatiotemporal gait variables were recorded bilaterally by the sensor software algorithms, capturing: gait speed (m/s), cadence (steps/min), step and stride lengths (m), percentages (%) of stance and swing phases, single-leg and double-leg stance durations, and propulsion metrics. Statistical Analysis PlanData normality was verified using the Shapiro-Wilk test. Continuous demographics are reported as mean and standard deviation (SD). Relative reliability was analyzed using Intraclass Correlation Coefficients (ICCs) with 95% confidence intervals (95% CIs). A two-way mixed-effects consistency model was selected for intra-rater reliability, and a two-way random-effects absolute agreement model was utilized for inter-rater reliability. Absolute reliability and precision were quantified calculating the Standard Error of Measurement. The Minimal Detectable Change was calculated to define the true clinical change threshold. Bland-Altman plotting was performed to identify systematic biases and calculate the limits of agreement (LoA).

研究の種類

観察的

入学 (実際)

24

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Madrid
      • Madrid、Madrid、スペイン、28045
        • Neuron Madrid Río

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

The study population consists of a convenience sample of adult stroke survivors receiving outpatient physical therapy and neurorehabilitation care. Participants include individuals with a confirmed diagnosis of either ischemic or hemorrhagic stroke, in both subacute and chronic stages (time since onset greater than one month), who retain the functional capacity to ambulate independently on overground surfaces without physical assistance. All participants are recruited from the outpatient facilities of a specialized neurorehabilitation center (Neuron Clinics) located in Madrid, Spain.

説明

Inclusion Criteria:

  • adults aged 18-85 years
  • confirmed diagnosis of stroke
  • ability to ambulate (FAC > 4), regardless of foot-up use
  • Capacity to walk 10m without stopping and repeat the trials 6 times across the session
  • Cognitive ability to understand the study instruction and provide written informed consent

Exclusion Criteria:

  • clinical instability or acute medical conditions that compromise gait safety
  • concomitant neurological conditions other than stroke
  • severe musculoskeletal disorders that interfere with gait analysis
  • balance or coordination impairments secondary to visual or auditory deficits
  • recent use of substances or medications that impair bait, balance, or postural control
  • pregnancy
  • cognitive or behavioral impairments that prevent the proper performance of the test

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Participants
All the participants included

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Intra-rater reliability of spatiotemporal gait parameters
時間枠:Up to 48 hours
Relative and absolute consistency of spatiotemporal gait metrics derived from repeated measurements taken by the same evaluator
Up to 48 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Inter-rater reliability of spatiotemporal gait parameters
時間枠:Day 1 and day 2
Relative and absolute consistency of spatiotemporal gait metrics recorder simultaneously by two independent, trained evaluators
Day 1 and day 2

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Alejandro Herrera Rojas, Physical Therapist、Neuron, Spain

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年10月10日

一次修了 (実際)

2026年4月20日

研究の完了 (実際)

2026年5月14日

試験登録日

最初に提出

2026年6月10日

QC基準を満たした最初の提出物

2026年6月10日

最初の投稿 (実際)

2026年6月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月16日

QC基準を満たした最後の更新が送信されました

2026年6月10日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • Baiobit validation in stroke

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Database used for the analyses will be published in zenodo website

IPD 共有時間枠

Data will be uploaded once analyzed

IPD 共有アクセス基準

Anybody

IPD 共有サポート情報タイプ

  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する